Skip to main content

Lodosyn Disease Interactions

There are 4 disease interactions with Lodosyn (carbidopa).

Major

Carbidopa (applies to Lodosyn) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

Carbidopa-levodopa products are contraindicated in patients with narrow-angle glaucoma.

References

  1. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
Major

Dopamine agonists (applies to Lodosyn) hypotension

Major Potential Hazard, Moderate plausibility.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. Hoehn MM (1975) "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol, 32, p. 50-1
  2. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y (1990) "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol, 30, p. 194-9
  3. (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
  4. (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals
  5. (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals
  6. (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
  7. (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
  8. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
  9. (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
  10. (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
  11. (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
View all 11 references
Major

Dopaminergic antiparkinson agents (applies to Lodosyn) psychosis

Major Potential Hazard, Moderate plausibility.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

References

  1. (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
  2. (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
  3. (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
  4. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
  6. (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
  7. (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
  8. (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
View all 8 references
Moderate

Carbidopa (applies to Lodosyn) depression

Moderate Potential Hazard, Moderate plausibility.

Caution and observation is recommended when treating patients with carbidopa, as depression with concomitant suicidal tendencies may develop or be exacerbated.

References

  1. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma

Lodosyn drug interactions

There are 3 drug interactions with Lodosyn (carbidopa).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer